The survey is conducted to investigate the safety and efficacy of long-term use of BI-Sifrol Tablets in Restless Legs Syndrome (RLS) patients with or without renal dysfunction in routine medical practice.
Study Type
OBSERVATIONAL
Enrollment
571
Incidence of Drug-related Adverse Events
Number of patients with drug-related adverse events
Time frame: 12 Months
Change From Baseline in Total Score of the International Restless Legs Syndrome Rating Scale (IRLS)
International Restless Legs Syndrome rating scale (IRLS): The IRLS rating scale is a selfrating scale used to evaluate the severity of RLS and the patients are requested to answer 10 questions on a scale of 0 to 4. Respective scores (0-4 points) for the 10 questions were added up to calculate the total score on the IRLS. Therefore the total score is 0-40. The lower values represent a better outcome.
Time frame: after 12 months or at the end of observation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Boehringer Ingelheim Investigational Site 119
Akashi, Japan
Boehringer Ingelheim Investigational Site 52
Akishima, Japan
Boehringer Ingelheim Investigational Site 16
Akita, Japan
Boehringer Ingelheim Investigational Site 22
Ami-machi, Japan
Boehringer Ingelheim Investigational Site 36
Asahi, Japan
Boehringer Ingelheim Investigational Site 1
Asahikawa, Japan
Boehringer Ingelheim Investigational Site 40
Chiba, Japan
Boehringer Ingelheim Investigational Site 158
Chōfu, Japan
Boehringer Ingelheim Investigational Site 78
Chūō, Japan
Boehringer Ingelheim Investigational Site 66
Fujisawa, Japan
...and 149 more locations